This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Willett, C. G. Articles by Ryan, D. P. Search for Related Content PubMed PubMed Citation Articles by Willett, C. G. Articles by Ryan, D. P. Social Bookmarking                            What's this?

Locally Advanced Pancreatic Cancer

Christopher G. Willett, Brian G. Czito, Johanna C. Bendell, David P. Ryan

From the Department of Radiation Oncology; Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA

Address reprint requests to Christopher Willet, MD, Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710; e-mail: willett{at}radonc.duke.edu.

Of the 32,180 patients diagnosed with pancreatic carcinoma in the United States this year, approximately 40% will present with locally advanced disease. Radiotherapeutic approaches are often employed because these patients have unresectable tumors by virtue of local invasion into the retroperitoneal vessels in the absence of clinically detectable metastases. These treatments include external-beam irradiation with and without fluorouracil-based chemotherapy, intraoperative irradiation, and, more recently, external-beam irradiation with new systemic targeted agents.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Klatte, D. B. Seligson, J. LaRochelle, B. Shuch, J. W. Said, S. B. Riggs, N. Zomorodian, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 894 - 900. [Abstract] [Full Text] [PDF]

				Y.-E. Kim, M.-S. Park, H.-S. Hong, C. M. Kang, J.-Y. Choi, J. S. Lim, W. J. Lee, M.-J. Kim, and K. W. Kim Effects of Neoadjuvant Combined Chemotherapy and Radiation Therapy on the CT Evaluation of Resectability and Staging in Patients with Pancreatic Head Cancer Radiology, March 1, 2009; 250(3): 758 - 765. [Abstract] [Full Text] [PDF]

				M.-S. Park, E. Klotz, M.-J. Kim, S. Y. Song, S. W. Park, S.-W. Cha, J. S. Lim, J. Seong, J. B. Chung, and K. W. Kim Perfusion CT: Noninvasive Surrogate Marker for Stratification of Pancreatic Cancer Response to Concurrent Chemo- and Radiation Therapy Radiology, January 1, 2009; 250(1): 110 - 117. [Abstract] [Full Text] [PDF]

				A. Marten, N. Zeiss, S. Serba, S. Mehrle, M. von Lilienfeld-Toal, and J. Schmidt Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma Mol. Cancer Ther., November 1, 2008; 7(11): 3624 - 3631. [Abstract] [Full Text] [PDF]

				S. Heinrich, B. C. Pestalozzi, M. Schafer, A. Weber, P. Bauerfeind, A. Knuth, and P.-A. Clavien Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head J. Clin. Oncol., May 20, 2008; 26(15): 2526 - 2531. [Abstract] [Full Text] [PDF]

				M. Tsujie, S. Nakamori, E. Tanaka, H. Nagano, K. Umeshita, K. Dono, M. Sakon, T. Inoue, T. Inoue, and M. Monden Phase I/II Trial of Hyperfractionated Accelerated Chemoradiotherapy for Unresectable Advanced Pancreatic Cancer Jpn. J. Clin. Oncol., August 1, 2006; 36(8): 504 - 510. [Abstract] [Full Text] [PDF]